Report cover image

RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Application (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 188 Pages
SKU # IRE18321712

Description

RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Application (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2023-2030


The RNA Therapy Market size was estimated at USD 1.84 billion in 2022 and expected to reach USD 2.18 billion in 2023, at a CAGR 21.90% to reach USD 8.98 billion by 2030.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the RNA Therapy Market.
  • Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA. The Enabling Technologies commanded largest market share of 63.41% in 2022, followed by Enabled Technologies.
  • Based on Application, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases. The Infectious Diseases commanded largest market share of 21.92% in 2022, followed by Oncology.
  • Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development. The Drug Discovery & Development commanded largest market share of 72.54% in 2022, followed by Diagnostics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.89% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the RNA Therapy Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape RNA Therapy Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the RNA Therapy Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the RNA Therapy Market?
  3. What is the competitive strategic window for identifying opportunities in the RNA Therapy Market?
  4. What are the latest technology trends and regulatory frameworks in the RNA Therapy Market?
  5. What is the market share of the leading vendors in the RNA Therapy Market?
  6. Which modes and strategic moves are suitable for entering the RNA Therapy Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

188 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. RNA Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Target Specificity and Selectivity of Treatment and Diagnostics
5.1.1.2. Strategic Alliances & Funding Supported By Pharmaceutical Companies
5.1.1.3. Increased Potential of Virtual Drug Development Models
5.1.2. Restraints
5.1.2.1. Hurdles In Drug Delivery Commercialization
5.1.3. Opportunities
5.1.3.1. Increasing Usage in Cell-Based Cancer Immunotherapy
5.1.3.2. Significance of mRNA Medicine to Treat Deficiency and Genetic Disorders
5.1.3.3. Pipelined Clinical Trials of RNA-Based Therapeutics
5.1.4. Challenges
5.1.4.1. Risk Associated with Investment & Potential Outcomes
5.2. Market Segmentation Analysis
5.2.1. Technology: Enabled technologies elevating the advancements in RNA therapies
5.2.2. End User: Utilization of RNA therapies in drug discovery & development
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. RNA Therapy Market, by Technology
6.1. Introduction
6.2. Enabled Technologies
6.3.1. Inhibition
6.3.2. Labeling
6.3.3. Linear amplification
6.3.4. Microarrays
6.3.5. Purification
6.3.6. qRT-PCR
6.3. Enabling Technologies
6.4.1. RNA Antisense Technologies
6.4.2.1. MicroRNA
6.4.2.2. Small interfering RNA
6.4.2. RNA Interference Technologies
7. RNA Therapy Market, by Application
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular
7.4. Genetic Disorders
7.5. Infectious Diseases
7.6. Kidney Diseases
7.7. Metabolic Disorders
7.8. Oncology
7.9. Retinal Diseases
8. RNA Therapy Market, by End User
8.1. Introduction
8.2. Academic Research
8.3. Diagnostics
8.4. Drug Discovery & Development
9. Americas RNA Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific RNA Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa RNA Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
12.3.2. Investment & Funding
12.3.2.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
12.3.2.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Alnylam Pharmaceuticals, Inc.
13.1.2. Arbutus Biopharma Corporation
13.1.3. Arcturus Therapeutics Holdings Inc.
13.1.4. Arrowhead Pharmaceuticals, Inc.
13.1.5. AstraZeneca PLC
13.1.6. Benitec Biopharma Limited
13.1.7. Biogen Inc.
13.1.8. BioNTech SE
13.1.9. Cartesian Therapeutics, Inc.
13.1.10. Cenix BioScience GmbH
13.1.11. Deep Genomics
13.1.12. Eli Lilly and Company
13.1.13. F. Hoffmann-La Roche AG
13.1.14. GSK PLC
13.1.15. Ionis Pharmaceuticals, Inc.
13.1.16. Laronde
13.1.17. MiNA Therapeutics Limited
13.1.18. Moderna, Inc.
13.1.19. NeuBase Therapeutics, Inc.
13.1.20. Nordic Nanovector ASA
13.1.21. Novartis AG
13.1.22. Novo Nordisk A/S
13.1.23. Nutcracker Therapeutics, Inc.
13.1.24. ProQR Therapeutics N.V.
13.1.25. Sanofi S.A.
13.1.26. Silence Therapeutics PLC
13.1.27. Sirnaomics, Inc.
13.1.28. Triplet Therapeutics, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us